1-(2-methoxy-5-trifluoromethyl-phenyl)-3-[3-(1-pyridin-4-yl-1H-imidazole-2-carbonyl)-phenyl]-urea | 900536-23-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-methoxy-5-trifluoromethyl-phenyl)-3-[3-(1-pyridin-4-yl-1H-imidazole-2-carbonyl)-phenyl]-urea
• 英文别名: 1-[2-Methoxy-5-(trifluoromethyl)phenyl]-3-[3-(1-pyridin-4-ylimidazole-2-carbonyl)phenyl]urea
• CAS: 900536-23-4
• 化学式: C₂₄H₁₈F₃N₅O₃
• 分子量: 481.434
• InChiKey: SIDXJVHMEFKPRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  98.1
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
  申请人：Jin Lee-Way

  公开号：US20070254889A1

  公开（公告）日：2007-11-01

  The present invention is directed to pharmaceutical compositions comprising one or more compounds of Formulae I, II, III, IV, V, VI, VII, VIII, IX and X, or pharmaceutically acceptable salts thereof and excipients. The present invention provides a method of inhibiting β-amyloid plaque aggregation, the method comprising introducing into a mammal an aggregation-inhibiting amount of a compound of Formula I, II, III, IV, V, VI, VII, VIII, IX or X or a pharmaceutically acceptable salt, ester, amide or prodrug thereof. By inhibiting amyloid aggregation, this method is capable of rescuing cells that otherwise would be susceptible or further damaged by amyloidosis.

  本发明涉及一种制药组合物，包括式I、II、III、IV、V、VI、VII、VIII、IX和X中的一个或多个化合物，或其药学上可接受的盐和辅料。本发明提供了一种抑制β-淀粉样斑块聚集的方法，该方法包括向哺乳动物中引入式I、II、III、IV、V、VI、VII、VIII、IX或X中的一种化合物或其药学上可接受的盐、酯、酰胺或前药的抑制聚集量。通过抑制淀粉样聚集，该方法能够挽救那些本来易受淀粉样蛋白病损伤的细胞。
• Certain substituted diphenyl ureas, as modulators of kinase activity
  申请人：Mitchell A. Scott

  公开号：US20060211738A1

  公开（公告）日：2006-09-21

  Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

  本文提供了从式1化合物中选择的某些化学实体和药学上可接受的盐、溶剂化合物、晶体形态、螯合物、非共价复合物、前药和混合物。本文还提供了包含至少一种化学实体和一个或多个药学上可接受的载体、佐剂和赋形剂的制药组合物。本文揭示了治疗对血管生成激酶调节有反应的某些疾病和疾病的患者的方法，包括向这些患者施用至少一种化学实体的有效量，以减少疾病或疾病的症状或体征。这些疾病包括癌症，包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。治疗方法包括将至少一种化学实体作为单个活性剂施用或将该至少一种化学实体与一个或多个其他治疗剂联合使用。一种用于确定样品中是否存在血管生成激酶的方法，包括将样品与至少一种化学实体接触，以允许检测血管生成激酶的活性水平，并从中确定样品中血管生成激酶的存在或缺失。
• 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP1858877A1

  公开（公告）日：2007-11-28
• US7625931B2
  申请人：——

  公开号：US7625931B2

  公开（公告）日：2009-12-01
• [EN] 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY<br/>[FR] UREES A SUBSTITUTION 1,3-DIARYLE, MODULATEURS DE L'ACTIVITE DE KINASES
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2006076592A1

  公开（公告）日：2006-07-20

  [EN] Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof , are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Use in treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom
  [FR] L'invention porte: sur certaines entités chimiques de formule (I) et leurs sels, solvates, formes cristallines, chélates, complexes non covalents, prodrogues, pharmacocompatibles, et leurs mélanges; sur des préparations pharmaceutiques comprenant au moins l'une de ces entités et un ou des véhicules choisis parmi des vecteurs adjuvants et excipients; sur leur utilisation pour traiter des patients souffrant de maladies ou troubles réagissant à la modulation de la kinase angiogène tels que des cancers, dont ceux du sein, de l'endomètre, du colon, et le carcinome squameux du col, consistant à leur administrer une dose d'au moins une de ces entités pour en réduire les signes ou les symptômes; et sur une méthode permettant de déterminer la présence ou l'absence d'une kinase angiogène dans un échantillon consistant à mettre l'échantillon en contact avec l'une au moins desdites entités dans des conditions permettant de détecter l'activité de ladite kinase, et son niveau.